Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
WuXi AppTec Co. (SS:603259) announced that its board has approved the distribution of a 2025 interim dividend, highlighting strong financial performance and confidence in future growth. The pharmaceutical and life sciences company will pay 3.50 yuan per 10 shares, with a total payout of 1 billion yuan scheduled for September 26, 2025.
Following the announcement, WuXi AppTec shares saw a positive market reaction. The company’s Hong Kong-listed stock rose 2.5% to HK$113.1, while its Shanghai-listed shares increased 0.7% to 109.55 yuan. Investors welcomed the dividend decision, viewing it as a sign of the company’s stable operations and optimistic outlook.
In its statement, WuXi AppTec emphasized that the payout reflects the board’s assessment of the firm’s operating results and overall financial strength. The move underscores the company’s strategy of rewarding shareholders while continuing to invest in long-term development across its global operations.
WuXi AppTec is a leading global provider of R&D and manufacturing services for the pharmaceutical, biotechnology, and medical device industries. With strong revenue streams and expanding international partnerships, the company remains positioned to benefit from rising demand in healthcare innovation.
The 2025 mid-year dividend marks another milestone for the company, reinforcing its track record of consistent shareholder returns. Market analysts noted that such decisions not only boost investor confidence but also support the stock’s long-term value in both Shanghai and Hong Kong markets.
By aligning its dividend strategy with solid financial results and a positive business outlook, WuXi AppTec continues to strengthen its reputation as a reliable growth-driven enterprise in China’s healthcare sector.
